8-K: Caribou Biosciences Reports Q4/FY25 Results, Advances CAR-T

Caribou Biosciences reported its fourth quarter and full year 2025 financial results, highlighting strong clinical progress for its allogeneic CAR-T cell therapy programs, vispa-cel and CB-011.

Summary

• Caribou Biosciences reported full year 2025 licensing and collaboration revenue of $11.2 million, an increase from $10.0 million in 2024.
• Research and development expenses decreased to $109.4 million for full year 2025 from $130.2 million in 2024, primarily due to workforce reduction and strategic pipeline prioritization.
• General and administrative expenses decreased to $37.9 million for full year 2025 from $46.5 million in 2024, driven by lower legal and personnel-related expenses.
• GAAP net loss for full year 2025 was $148.1 million, or $1.59 per share, a slight improvement from $149.1 million, or $1.65 per share, in 2024.
• Non-GAAP net loss for full year 2025 was $126.8 million, or $1.36 per share, compared to $149.1 million, or $1.65 per share, in 2024, excluding $21.3 million in non-cash impairment charges.
• Cash, cash equivalents, and marketable securities stood at $142.8 million as of December 31, 2025, down from $249.4 million as of December 31, 2024.
• The company expects its current cash to fund operations into the second half of 2027, including dose expansion for CB-011 and start-up activities for the planned vispa-cel pivotal trial.
• Vispa-cel (CB-010) ANTLER phase 1 data in second-line LBCL patients demonstrated efficacy and durability on par with autologous CAR-T therapy.
• Caribou is in ongoing engagement with the FDA regarding the design of the pivotal trial for vispa-cel in 2L LBCL.
• CB-011 CaMMouflage phase 1 clinical trial for relapsed or refractory multiple myeloma initiated dose expansion, with data correlating CAR-T cell expansion with deep, durable responses.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive update. Strong clinical progress and improved operational efficiency are encouraging, but the significant cash burn and explicit mention of needing to raise capital for the pivotal trial introduce a degree of financial uncertainty.

Positives

• Full year 2025 licensing and collaboration revenue increased to $11.2 million from $10.0 million in 2024.
• Research and development expenses decreased by $20.8 million year-over-year, reflecting cost management and strategic prioritization.
• General and administrative expenses decreased by $8.6 million year-over-year, indicating improved operational efficiency.
• Non-GAAP net loss significantly improved to $126.8 million in 2025 from $149.1 million in 2024, demonstrating better underlying operational performance.
• Vispa-cel ANTLER phase 1 data showed efficacy and durability comparable to autologous CAR-T therapies in second-line LBCL patients, supporting its potential as a best-in-class allogeneic therapy.
• Vispa-cel has received Regenerative Medicine Advanced Therapy (RMAT), Fast Track, and Orphan Drug designations from the FDA.
• CB-011 CaMMouflage phase 1 trial initiated dose expansion, with translational data supporting the selected regimen and correlating CAR-T cell expansion with durable responses.
• CB-011 has been granted Fast Track and Orphan Drug designations by the FDA.

Negatives

• Cash, cash equivalents, and marketable securities decreased significantly to $142.8 million as of December 31, 2025, from $249.4 million as of December 31, 2024, indicating substantial cash burn.
• Incurred $21.3 million in non-recurring, non-cash impairment charges for full year 2025, related to strategic pipeline prioritization and an impairment of a stock investment.
• The company is exploring multiple options to fully fund its planned vispa-cel pivotal trial, indicating a potential need for additional capital.

Risks

• Risks inherent in the development of allogeneic CAR-T cell therapy products.
• Uncertainties related to the initiation, cost, timing, progress, and results of current and future clinical trials.
• The risk that initial, preliminary, or interim clinical trial data will not ultimately be predictive of the safety and efficacy of CAR-T cell therapy product candidates.
• The risk that clinical outcomes may differ as patient enrollment continues and as more patient data becomes available.
• The risk that different conclusions or considerations are reached once additional data have been received and fully evaluated.
• The ability to obtain key regulatory input and approvals.
• Risks related to limited operating history, history of net operating losses, financial position, and the ability to raise additional capital as needed to fund operations and product candidate development, including the pivotal phase 3 clinical trial for vispa-cel.
• Caution should be exercised when interpreting results from separate trials involving commercially approved autologous CAR-T cell therapies, as cross-trial comparisons may have no interpretive value due to material differences in trial design, patient population, and treatment protocols.

Future Outlook

Caribou expects to report longer follow-up data from the ANTLER phase 1 clinical trial for vispa-cel later in 2026. For CB-011, initial dose expansion data and longer follow-up on dose escalation data from the CaMMouflage phase 1 clinical trial are also anticipated in 2026. The company is in ongoing discussions with the FDA regarding the design of the pivotal trial for vispa-cel. Caribou projects its current cash, cash equivalents, and marketable securities will be sufficient to fund its operating plan, including CB-011 dose expansion and vispa-cel pivotal trial start-up activities, into the second half of 2027. The company is actively exploring multiple options to fully fund the planned vispa-cel pivotal trial.

Management Comments

• "2025 was a year of strong execution for Caribou as we advance two potentially best-in-class allogeneic CAR-T cell therapy programs."
• "The vispa-cel ANTLER phase 1 data in second-line LBCL patients demonstrated efficacy and durability on par with autologous CAR-T therapy and solidified our confidence that this program is delivering on the promise of an off-the-shelf CAR-T cell therapy with speed, scalability, and access."

Industry Context

StockSavvy.ai notes that Caribou Biosciences is positioned in the highly competitive and rapidly evolving allogeneic CAR-T cell therapy space. The company's focus on 'off-the-shelf' therapies aims to address the logistical and accessibility challenges inherent in current autologous CAR-T treatments. The reported clinical data for vispa-cel, demonstrating efficacy and durability 'on par with autologous CAR-T therapy,' is a significant indicator of progress in validating the potential of allogeneic approaches. The advancement of both vispa-cel and CB-011 into later-stage development or dose expansion phases suggests Caribou is maintaining a competitive pace in bringing these innovative therapies to market, despite the substantial capital requirements typical for biopharmaceutical development.

Comparison to Industry Standards

• Vispa-cel ANTLER phase 1 data in second-line LBCL patients demonstrated efficacy and durability on par with autologous CAR-T therapy. This comparison is made against commercially approved autologous CAR-T cell therapies, which are considered the current standard of care for certain hematologic malignancies.
• The filing explicitly cautions that results from separate trials involving commercially approved autologous CAR-T cell therapies (not conducted by Caribou) may not be comparable to vispa-cel's clinical results due to material differences in trial design, duration, patient population, patient characteristics, clinical trial phase, treatment protocols, and investigators.
• Caribou's allogeneic approach with PD-1 knockout for vispa-cel and B2M knockout with B2M-HLA-E fusion protein for CB-011 represents an attempt to overcome limitations of existing therapies by enhancing CAR-T cell activity and blunting immune-mediated rejection, respectively, aiming for a 'best-in-class' profile.

Stakeholder Impact

• **Shareholders:** Potential for increased value if clinical trials continue to show positive results and lead to regulatory approval, but also dilution risk from potential future capital raises.
• **Patients:** Continued progress in developing potentially transformative allogeneic CAR-T cell therapies for B cell non-Hodgkin lymphoma and multiple myeloma offers hope for new treatment options.
• **Employees:** Previous reduction in workforce and strategic pipeline prioritization indicate ongoing adjustments to optimize operations and focus resources.
• **Regulatory Authorities:** Ongoing engagement with the FDA for pivotal trial design for vispa-cel indicates active collaboration and adherence to regulatory pathways.

Next Steps

• Engage with the FDA on the pivotal trial design for vispa-cel in second-line LBCL.
• Report longer follow-up data from the ANTLER phase 1 clinical trial for vispa-cel in 2026.
• Report initial dose expansion data for CB-011 from the CaMMouflage phase 1 clinical trial in 2026.
• Report longer follow-up on dose escalation data for CB-011 from the CaMMouflage phase 1 clinical trial in 2026.
• Participate in a fireside chat at the Leerink 2026 Global Healthcare Conference on March 10, 2026.

Key Dates

Recommendation

The clinical progress for vispa-cel and CB-011 is promising, with data suggesting competitive efficacy for an allogeneic therapy. The improved non-GAAP net loss indicates better operational control. However, the substantial cash burn and the explicit need to raise significant capital for the pivotal vispa-cel trial introduce considerable financial risk and potential dilution. While the long-term potential is high, the near-term funding uncertainty warrants a 'hold' position, advising investors to await more clarity on the pivotal trial funding and further clinical data.

Keywords

CRISPR, genome editing, CAR-T cell therapy, allogeneic, vispa-cel, CB-011, B cell non-Hodgkin lymphoma, multiple myeloma, clinical trial, biopharmaceutical, oncology, financial results, biotech